Showing results (121-130 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|March 24, 2022
UACA locus is associated with breast cancer chemoresistance and survivalQianqian Zhu, Emily Schultz, Jirong Long, et al.
NPJ Breast Cancer|April 21, 2023
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancerDanyang Zhou, Mei Li, Mohamed Hussein Yasin, et al.
NPJ Breast Cancer|May 6, 2023
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patientsJincong Q Freeman, Sarah Shubeck, Frederick M Howard, et al.
NPJ Breast Cancer|May 13, 2023
Immune landscape of breast tumors with low and intermediate estrogen receptor expressionLeonie Voorwerk, Joyce Sanders, Milou S Keusters, et al.
NPJ Breast Cancer|May 20, 2023
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancerAnthony D Elias, Nicole S Spoelstra, Alyse W Staley, et al.
NPJ Breast Cancer|April 17, 2021
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohortThomas Grinda, Natacha Joyon, Amélie Lusque, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
NPJ Breast Cancer|May 10, 2023
Reversion of breast epithelial polarity alterations caused by obesityJulia Holmes, Mohamed Gaber, Mónica Z Jenks, et al.
NPJ Breast Cancer|May 10, 2023
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancerZiyan Yang, Jianguo Feng, Ji Jing, et al.
NPJ Breast Cancer|May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
Pageof 98